Deseret Mutual Benefit Administrators Sells 1,077 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Deseret Mutual Benefit Administrators decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 17,064 shares of the biopharmaceutical company’s stock after selling 1,077 shares during the quarter. Gilead Sciences comprises approximately 0.8% of Deseret Mutual Benefit Administrators’ portfolio, making the stock its 21st biggest holding. Deseret Mutual Benefit Administrators’ holdings in Gilead Sciences were worth $1,576,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in GILD. HHM Wealth Advisors LLC increased its holdings in Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 154 shares during the period. Valued Wealth Advisors LLC grew its position in shares of Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 161 shares in the last quarter. YANKCOM Partnership bought a new position in shares of Gilead Sciences in the fourth quarter worth $28,000. Decker Retirement Planning Inc. purchased a new stake in shares of Gilead Sciences in the fourth quarter worth $29,000. Finally, Crews Bank & Trust bought a new stake in Gilead Sciences during the fourth quarter valued at $31,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on GILD shares. Oppenheimer upped their target price on Gilead Sciences from $105.00 to $115.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 10th. Piper Sandler raised their target price on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an “overweight” rating in a research note on Wednesday, February 12th. Cantor Fitzgerald reiterated a “neutral” rating and set a $80.00 target price on shares of Gilead Sciences in a research report on Wednesday, December 11th. Morgan Stanley increased their price target on shares of Gilead Sciences from $113.00 to $123.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. Finally, The Goldman Sachs Group lifted their price objective on shares of Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a report on Wednesday, February 12th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $102.08.

Insider Buying and Selling at Gilead Sciences

In other news, Director Jeffrey Bluestone sold 6,788 shares of the business’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total value of $620,355.32. Following the sale, the director now directly owns 8,920 shares of the company’s stock, valued at $815,198.80. The trade was a 43.21 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 248,645 shares of the firm’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $92.76, for a total value of $23,064,310.20. Following the transaction, the chief financial officer now directly owns 138,919 shares of the company’s stock, valued at approximately $12,886,126.44. This trade represents a 64.16 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 713,000 shares of company stock valued at $67,945,181. 0.16% of the stock is currently owned by corporate insiders.

Gilead Sciences Stock Down 0.1 %

NASDAQ GILD opened at $109.95 on Friday. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $111.03. The stock has a market capitalization of $137.03 billion, a PE ratio of 297.16, a PEG ratio of 0.90 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The business’s 50-day moving average is $95.41 and its 200 day moving average is $88.63.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Sell-side analysts forecast that Gilead Sciences, Inc. will post 7.94 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be issued a $0.79 dividend. The ex-dividend date is Friday, March 14th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a yield of 2.87%. Gilead Sciences’s dividend payout ratio (DPR) is 832.43%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.